Sanofi Maintains Its Position
Throughout the proceedings, Sanofi has stood firm on its defense. The company has consistently argued that there is “no reliable scientific evidence” linking Zantac to cancer.
Still, the drugmaker has been pursuing settlements nationwide. In April 2024, Sanofi said it was working to resolve around 4,000 similar cases across the U.S. The Connecticut deals mark a notable step in that broader effort.
Other Drugmakers Under Pressure
Sanofi is not alone in facing claims tied to Zantac. GlaxoSmithKline (GSK) reached its own settlements in June this year to resolve its portion of the same Connecticut cases.
The plaintiffs in the Connecticut suits are represented by Brenden P. Leydon of Wocl Leydon LLC. Sanofi is represented by Joseph W. Martini and Armel L. Jacobs of Spears Manning & Martini LLC.
A Nationwide Litigation Landscape
The Connecticut settlements are only part of a sprawling wave of litigation testing the boundaries of liability in pharmaceutical law. With thousands of cases pending in courts nationwide, the Sanofi Zantac cancer suit continues to be a bellwether for how courts — and companies — will navigate allegations that strike at the intersection of medicine, science, and corporate accountability.
